It is sometimes observed that a boy who is good in studies also excels in sports. But can you imagine a drug eradicating one life-threatening disease equally capable of combating another complicated disorder? Well it is quite possible.
Recently Korean scientists at Samsung Medical Center in Seoul has discovered that Gleevec is succesful in reducing the leading cause of diabetes type II. But originally it is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.
Gleevec is marketed by Novartis. Its chemical name is imatinib mesilate( a salt of Imatinib).
It has been administered to patients suffering from diabetes type 2 who have shown positive improvements. There have been previous reports on Gleevec’s potential to treat diabetes but this is the first time scientists have proved the drug’s effectiveness.